$-0.67 EPS Expected for Karyopharm Therapeutics Inc. (KPTI)

April 21, 2018 - By Marry Poplack

Investors sentiment decreased to 1.56 in 2017 Q4. Its down 0.94, from 2.5 in 2017Q3. It dived, as 4 investors sold Karyopharm Therapeutics Inc. shares while 21 reduced holdings. 11 funds opened positions while 28 raised stakes. 30.26 million shares or 8.41% more from 27.91 million shares in 2017Q3 were reported.
7,123 were accumulated by Bnp Paribas Arbitrage. Morgan Stanley stated it has 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Group invested in 0% or 22,766 shares. The Connecticut-based Point72 Asset Mgmt Limited Partnership has invested 0.14% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Fincl Bank Of America De accumulated 42,559 shares. Citadel Lc holds 0% or 54,308 shares. Moreover, Northern Trust has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 385,717 shares. Raymond James invested in 0% or 19,734 shares. Susquehanna International Group Inc Llp accumulated 47,490 shares. D E Shaw Commerce Inc invested in 72,771 shares. Millennium Mgmt Ltd Liability, New York-based fund reported 436,836 shares. Vanguard Gru accumulated 0% or 1.80 million shares. Prudential accumulated 19,130 shares. Macquarie Gp accumulated 900 shares. Ameritas Ptnrs Inc has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI).

Since December 11, 2017, it had 0 buys, and 23 sales for $2.49 million activity. Another trade for 10,000 shares valued at $124,829 was sold by Shacham Sharon. Kauffman Michael also sold $100,769 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Monday, January 8. $40,000 worth of stock was sold by Mirza Mansoor Raza on Monday, March 5.

Analysts expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report $-0.67 EPS on May, 3.They anticipate $0.04 EPS change or 5.63 % from last quarter’s $-0.71 EPS. After having $-0.80 EPS previously, Karyopharm Therapeutics Inc.’s analysts see -16.25 % EPS growth. The stock decreased 1.22% or $0.18 during the last trading session, reaching $14.59. About 689,873 shares traded or 53.62% up from the average. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 23.92% since April 21, 2017 and is uptrending. It has outperformed by 12.37% the S&P500.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Ratings Coverage

Among 6 analysts covering Karyopharm Therapeutics (NASDAQ:KPTI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Karyopharm Therapeutics had 10 analyst reports since November 2, 2017 according to SRatingsIntel. As per Thursday, January 11, the company rating was maintained by H.C. Wainwright. The rating was reinitiated by H.C. Wainwright on Wednesday, November 15 with “Buy”. Robert W. Baird maintained the stock with “Buy” rating in Thursday, March 15 report. JP Morgan maintained Karyopharm Therapeutics Inc. (NASDAQ:KPTI) rating on Tuesday, April 10. JP Morgan has “Overweight” rating and $20 target. As per Friday, March 16, the company rating was maintained by JP Morgan. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Buy” rating given on Friday, March 16 by Jefferies. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Buy” rating by RBC Capital Markets on Thursday, November 2. The stock has “Buy” rating by H.C. Wainwright on Tuesday, December 12. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Buy” rating given on Friday, March 2 by RBC Capital Markets. The rating was maintained by Canaccord Genuity with “Buy” on Monday, March 12.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $724.43 million. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: